ESPR Projected Dividend Yield
Esperion Therapeutics Inc (New) ( NASDAQ : ESPR )Esperion Therapeutics, Inc. is a pharmaceutical company. Co. is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Co.'s products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Co.'s NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). 21 YEAR PERFORMANCE RESULTS |
ESPR Dividend History Detail ESPR Dividend News ESPR Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |